Feeds:
Posts
Comments

Posts Tagged ‘xience’

AstraZeneca‘s Crestor reduces risk of blood clots in the veinsA new analysis from the JUPITER study shows that CRESTOR® (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

Abbott gets a boost with stent results – Abbott Laboratories‘ drug-coated stent, Xience V, is significantly more effective than Boston Scientific Corp.’s Taxus three years after implantation in an artery, according to new long-term data. The data, presented Sunday at the American College of Cardiology meeting in Orlando, Fla., come from a 300-patient, Abbott-sponsored international trial known as SPIRIT II. The data are the longest to date for Abbott’s market-leading stent. Boston Scientific also markets Xience, which was approved last year, under the name Promus.

TriLipix for cholesterol: looking goodA combination of Abbott Laboratories’  new TriLipix triglycerides medicine and a low dose of AstraZeneca Plc’s Crestor cholesterol drug proved better than the individual pills in helping improve heart risk factors, researchers said. The combination did significantly better at lowering bad LDL cholesterol and other blood fats called triglycerides, as well as raising levels of good HDL cholesterol in patients with complex lipid disorders.

PLUS – Eli Lilly on mega-mergers: No“I think we are seeing deals that are really driven more by weakness than what I would describe as strong strategic combinations … That will improve short-term problems but fail to answer the long-term question of research productivity.”

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

There’s a ton of stuff going on this week, plus we’re in pre-ASCO mode (so lots of oncology news – scroll down for those headlines). Here we go:

What’s a vaptan? Maybe something pretty exciting – A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, brain hemorrhage, psychotic disorders and glaucoma, Belgian researchers report…more

One less tree in that Forest – Forest Laboratories Inc has ended its agreement with Daiichi Sankyo Co Ltd to co-promote Daiichi’s blood-pressure drug Azor, as Forest shifts resources to support other products, the companies said on Monday…more

Viagra: good for MD? – Researchers found the way the drug works to combat impotence may also help ward off heart failure in muscular dystrophy patients…more

OK, it’s not pharma per se, but it’s way too cool: Nanohealing – A startup based in Cambridge, MA, says that it plans to soon begin clinical trials of a nanostructured material that stops bleeding almost instantly…more

Here’s a switch: the FDA downgrading a warning – The FDA has eased restrictions on drugs used to enhance ultrasound images of the heart…more

Abbott’s new stent looking very good: interesting backstory – Abbott said this morning that its Xience stent outperformed Boston Scientific’s Taxus on several measures in a two-year study. The results mean the stent is likely to get the green light from the FDA soon…more

Merck and Ranbaxy: let’s develop something together – Merck signed a deal on Monday with Indian generics giant Ranbaxy to codevelop a new line of anti-infectives. As part of the agreement, Ranbaxy stands to receive more than $100 million for each drug that passes a certain milestone. That’s on top of an undisclosed upfront payment…more

Takeda’s financial results hiccup: no surprise when you’re buying another company!Japan’s largest drug manufacturer, Takeda Pharmaceutical, reported on Friday its first operating profit decline in 16 years and warned that the net profit in fiscal 2009 would diminish by more than a half as a result of its recent $8.8 billion deal to buy Millennium Pharmaceuticals in the United States…more

Daiichi Sankyo: the ups and downs of growth – Daiichi Sankyo Co., Japan’s third- largest drugmaker, had a 44 percent jump in quarterly net income, led by higher sales of its blood pressure treatments. The company predicts profit will drop this year…more

Trasylol bows out – Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the U.S. market after a long-awaited study found it raised the risk of death compared to two alternatives, U.S. regulators said on Wednesday…more

Diabetes beating cholesterol on spending – Diabetes treatments are now the leading driver of prescription drug spending growth, displacing lipid-lowering drugs which fell precipitously after a decade of reigning in the top position, as generic drugs cut the cost of treating high cholesterol…more

The heartbreak of psoriasis to be lessened soon? – A top Johnson & Johnson research official said on Wednesday the company’s experimental drug ustekinumab could become the “gold standard” for treating psoriasis, in part because it would require only four injections a year…more

J&J gets crossed off in court – Remember that truth-is-stranger-than-fiction drama that featured Johnson & Johnson suing the American Red Cross over the use of the red cross logo? Turns out it’s not going so well for J&J. A judge today threw out most of what was left of the case, the Associated Press reportsmore

On the Oncology/pre-ASCO front:

Cancer drugs: the big growth area? – Sales of cancer drugs will grow at nearly double the rate of the global pharmaceutical market and could reach $80 billion by 2012, according to IMS Health, which tracks prescription drug sales…more

Can cancer cure Pfizer?

Novartis’ experimental RAD001 making strides with kidney cancer – Nearly two-thirds of kidney cancer patients taking Novartis AG’s RAD001 had progression of their disease delayed by a year, a significantly better result than in those taking placebo, investigators said…more

Novartis’ Zometa may slow cancer progression: A drug prescribed to prevent fractures in breast cancer patients whose tumors have spread may actually help slow the cancer itself, U.S. researchers reported on Thursday…more

Pharmalot has links to some other early ASCO news, including Avastin, Herceptin, Vectibix, Denosumab, and Alimta.

Read Full Post »

Glaxo buying Reliant – GlaxoSmithKline Plc has agreed to buy privately held heart drug specialist Reliant Pharmaceuticals for $1.65 billion in cash, in a move to boost its flagging drug sales in the United States…more

J&J says good-bye to $440 mil – Johnson & Johnson said on Thursday its fourth-quarter results would include a special after-tax, noncash charge of $440 million from a write-down related to a decline in sales of acute heart failure drug Natrecor…more

Fountain of youth? – Scientists at Sirtris Pharmaceuticals Inc. say they have created a drug that mimics the ingredient in red wine linked to longevity and the cell structures that power endurance athletes like cycling champion Lance Armstrong. The new molecule is 1,000 times more potent than the wine derivative, resveratrol, and could lead to solutions for diseases of aging, including cancer and diabetes, according to authors of a study in today’s issue of the journal Nature…more

Abbott‘s Xience stent showing good side effect profile and efficacy…gets FDA panel green light – Abbott Laboratories Inc  won a U.S. advisory panel’s support on Thursday for an experimental drug-coated stent for heart patients. A committee of advisers to the Food and Drug Administration voted 9-1 to recommend approval of the device, called Xience. The FDA usually follows panel recommendations…more

On the Oncology front…

Novartis gets EU approval for Tasigna – Novartis AG (NVS) Wednesday said that Tasigna, a potential follow-up to Gleevec, the Swiss drugmaker’s second best-selling drug, won European Union approval for the treatment of a certain form of leukemia. Novartis, based in Basel, said Tasigna is a new targeted cancer drug for patients with a form of the life-threatening blood cancer chronic myeloid leukemia, who are resistant or intolerant to treatment with Gleevec. Novartis expects Tasigna to eventually replace Gleevec and plans to test its efficacy and safety in patients who haven’t yet been treated with Gleevec…more

Celgene‘s Revlimid combined with dexamethasone effective for multiple myeloma – A combination drug regimen that includes a derivative of thalidomide extended survival, as well as the time it took for the disease to reappear, in patients with multiple myeloma…more

Freeze tumors, reduce pain – Freezing tumors may help relieve the extreme pain of cancer that has spread to the bone, which is often untouched by narcotics or radiation, U.S. researchers said on Tuesday. This freezing process, called cryoablation, is often used to destroy kidney, prostate and other tumors, but researchers at the Mayo Clinic in Rochester, Minnesota, found it eased cancer pain in 80 percent of patients in a small study, and the effect lasted for up to six months…more

It’s not drugs, but it’s fascinating – Vivek Rangnekar, a University of Kentucky College of Medicine professor of radiation medicine and a team of researchers say they have found a tumor-suppressor gene called “Par-4” in the prostate. The researchers discovered that the Par-4 gene kills cancer cells, even highly aggressive types, but not normal cells, according to a study published in the journal Cancer Research and funded by grants from the National Institutes of Health. Rangnekar’s study found that mice born with this gene do not develop tumors. They grow normally, have no defects and actually live a few months longer than the control animals…more

Read Full Post »